Genmab AS Financial Analysis

• Publication date: April 2009

Genmab is developing the drugs in the areas Oncology, infectious diseases, rheumatoid arthritis and other inflammatory conditions. The industry player is using HuMAb-Mouse transgenic mouse technology, licensed from Medarex for developing human high affinity antibodies with less allergic responses or other side effects. Genmab has developed UniBody, a proprietary technology to create a smaller antibody format. The industry player is holding the l...

Genmab is developing the drugs in the areas Oncology, infectious diseases, rheumatoid arthritis and other inflammatory conditions. The industry player is using HuMAb-Mouse transgenic mouse technology, licensed from Medarex for developing human high affinity antibodies with less allergic responses or other side effects. Genmab has developed UniBody, a proprietary technology to create a smaller antibody format. The industry player is holding the licenses and other proprietary rights for human antibody technology and antibody products.

Global Industry s Direct, the leading business information provider, presents an in-depth business, strategic and financial analysis of Genmab AS. This company report analyses all strategic aspect of the company , including organisation and operations, key employees and competitive landscape . The hallmark of the report is the detailed strategic analysis and Global Industry s Direct’s views on the firm .

Report Coverage

-The firm ’s strengths and weaknesses and growth areas or decline are analyzed. The company is analyzed at financial, strategic and operational levels .
-The opportunities open to the industry player are considered and its growth opportunities assessed. .
-The report contains critical industry player information – organisation and operations, the industry player history, major products and services, competitive landscape , key employees and key employees , different locations and important subsidiaries.
-It provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
-Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why Should You Get This Report?

-A quick “one-stop-shop” to get the full picture regarding the company's strategic activity .
-Enhance business/sales activities by understanding customers’ businesses better.
-Get detailed information and financial & strategic analysis on industry players operating in your market .
-Identify prospective partners and suppliers – with key data on their businesses and locations.
-Capitalize on competitors’ weaknesses and target the industry opportunities available to them.
-Compare your firm ’s financial trends with those of your peers / competitors.
-Scout for potential take over targets, with detailed insight into the firms ’ strategic, financial and operational performance.

Global Pharmaceutical Industry

Data table Of Contents
Key Information 1
Key Ratios 1
Share Data 1
Performance Chart 1
Data table Of Contents 2
List of Tables 3
List of Figures 3
Key Facts 4
Company Overview 4
Major Products and Services 4
Overview 4
History 5
SWOT Analysis Overview 7
Overview 7
Genmab A/S - Strengths (SWOT Analysis) 7
Strong Focus on Research and Development Activities 7
Distinctive Technology 7
Partnerships 7
Genmab A/S - Weaknesses (SWOT Analysis) 7
Depenence on Third Party Sales s 7
Genmab A/S - Opportunities (SWOT Analysis) 7
CD 20 Programs 7
Collaboration with Medarex 8
Product Pipeline 8
Emerging March kets 8
Rising Healthcare Expenditure in the US 8
Genmab A/S - Threats (SWOT Analysis) 8
Inherent Uncertainties in Pharmaceutical Research and Development 8
Tightening of the FDA’s Regulatory Oversight 8
Cost Controlling Measures 9
Impact of the Financial Crisis 9
Industry Consolidation 9
Key Competitors 10
Key Employees 10
Key Employee Biographies 11
Company Statement 12
Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Financial Ratios 14
Capital March ket Ratios 14
Annual Ratios 14
Interim Ratios 15
Ratio Charts 16
Appendix 17
Methodology 17
Ratio Definitions 17
About World March kets Direct 20
Contact Us 20
Disclaimer 20
List of Tables
Genmab A/S, Major development 1
Genmab A/S, Key Ratios 1
Genmab A/S, Share Data 1
Genmab A/S, Major development 4
Major Products and Services 4
Genmab A/S, History 5
Genmab A/S, Key Executives 10
Genmab A/S, Key Employee Biographies 11
Genmab A/S, Other Locations 13
Genmab A/S, Ratios based on current share price 14
Genmab A/S, Annual Ratios 14
Genmab A/S, Interim Ratios 15
Currency Codes 17
Capital March ket Ratios 17
Equity Ratios 17
Profitability Ratios 18
Cost Ratios 18
Liquidity Ratios 18
Leverage Ratios 19
Efficiency Ratios 19
List of Figures
Genmab A/S, Performance Chart (2004 - 2008) 1
Genmab A/S, Ratio Charts 16

Pharmaceutical in World

Cuba Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Cuba, World

Fiji Poisonings, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Fiji, World

Cook Islands Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World

Iran Poisonings, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Iran, World

Saint Vincent Poisonings, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World